Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow in Hematology-Oncology, Medicine, Duke University 2008
  • Fellow in Hematology-Oncology, Medicine, University of Pennsylvania 2005 - 2007
  • Resident, Medicine, University of North Carolina at Chapel Hill 2001 - 2004
  • M.D., Drexel University 2001
• 

  Duke Appointment History

  • Medical Instructor in the Department of Medicine, Medicine, Hematology, Medicine 2008 - 2012
  • Instructor, Temporary in the Department of Medicine, Medicine, Hematology, Medicine 2008
• Research
• 

  Selected Grants

  • Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES) awarded by Ablynx 2016 - 2021
  • Transfusion Medicine and Hematology awarded by National Institutes of Health 1975 - 2021
  • POST-MARKETING non-interventional safety evaluation of obizur in the treatment of bleeding episodes for patients with acquired hemophilia A awarded by Baxalta, Inc. 2016 - 2020
  • An open-label, multicenter, Post-Marketing Requirement study to investigate the safety and tolerability of octaplas in the management of pediatric patients who require therapeutic plasma exchange awarded by Octapharma AG 2017 - 2018
  • OMS721 in TMA awarded by Omeros 2014 - 2018
  • Microfluidic quartz resonator based blood plasma coagulation monitors awarded by Qatch Technologies LLC 2017 - 2018
  • ART Study (Rituximab as adjunct therapy with plasma exchange in TTP patients) awarded by Washington University School of Medicine 2015 - 2018
  • Edoxaban in VTE Associated with Cancer Hokusai VTE Cancer Study DU176b-D-U311 awarded by Daiichi Sankyo Inc 2015 - 2018
  • A Phase III Trial with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura awarded by Ablynx 2016 - 2017
  • RE-VERSE-AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial awarded by Boehringer Ingelheim Pharmaceuticals, Inc. 2015 - 2017
  • Public Health Surveillance of Bleeding awarded by Centers for Disease Control and Prevention 2011 - 2016
  • GSK AML awarded by GlaxoSmithKline 2013 - 2016
• Publications & Artistic Works
• 

  Selected Publications

  • Journal Articles

    • Diep, R, and Metjian, A. "A rare CALR variant mutation and a review of CALR in essential thrombocythemia (Accepted)." Journal of Thrombosis and Thrombolysis (February 6, 2018): 1-6.  Full Text
    • Tanhehco, YC, Arepally, G, and Metjian, A. "Novel therapeutic approaches for thrombotic thrombocytopenic purpura." Current opinion in hematology 24, no. 6 (November 2017): 521-528.  Full Text
    • Abbes, S, Metjian, A, Gray, A, Martinu, T, Snyder, L, Chen, D-F, Ellis, M, Arepally, GM, and Onwuemene, O. "Human Leukocyte Antigen Sensitization in Solid Organ Transplantation: A Primer on Terminology, Testing, and Clinical Significance for the Apheresis Practitioner." Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 21, no. 5 (October 2017): 441-450. (Review)  Full Text
    • Metjian, A, Tanhehco, YC, Aqui, N, Bhoj, VG, Jamensky, L, Marques, MB, Onwuemene, O, Pham, HP, and Arepally, GM. "The thrombotic microangiopathy Registry of North America: A United States multi-institutional TMA network." Journal of clinical apheresis 31, no. 5 (October 2016): 448-453.  Full Text
    • Metjian, AD. "rVWF: treatment finally reaches the modern age." Blood 126, no. 17 (October 2015): 1975-1976.  Full Text
    • Nipp, R, Mitchell, A, Pishko, A, and Metjian, A. "Waldenström macroglobulinemia in hepatitis C: case report and review of the current literature." Case reports in oncological medicine 2014 (January 2014): 165670-.  Full Text
    • Patil, AS, Dotters-Katz, SK, Metjian, AD, James, AH, and Swamy, GK. "Use of a thrombopoietin mimetic for chronic immune thrombocytopenic purpura in pregnancy." Obstetrics and gynecology 122, no. 2 Pt 2 (August 2013): 483-485.  Full Text
    • Sood, SL, Cuker, A, Wang, C, Metjian, AD, Chiang, EY, Soucie, JM, Konkle, BA, and HTCN Study Investigators, . "Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A." Haemophilia 19, no. 4 (July 2013): 595-601.  Full Text  Link to Item
    • Sood, SL, Cuker, A, Wang, C, Metjian, AD, Chiang, EY, Soucie, JM, and Konkle, BA. "Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A." Haemophilia 19, no. 4 (2013): 595-601.  Full Text
    • Lee, G, Duan-Porter, W, and Metjian, AD. "Acquired, non-amyloid related factor X deficiency: review of the literature." Haemophilia : the official journal of the World Federation of Hemophilia 18, no. 5 (September 2012): 655-663. (Review)  Full Text
    • Silbermins, D, and Metjian, AD. "Hematology." Medical Secrets (2012): 404-448.  Full Text
    • Whitlatch, NL, Kong, DF, Metjian, AD, Arepally, GM, and Ortel, TL. "Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia." Blood 116, no. 10 (September 9, 2010): 1761-1766.  Full Text  Link to Item
    • Metjian, AD, Wang, C, Sood, SL, Cuker, A, Peterson, SM, Soucie, JM, Konkle, BA, and HTCN Study Investigators, . "Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease." Haemophilia 15, no. 4 (July 2009): 918-925.  Full Text  Link to Item
    • Metjian, A, and Abrams, CS. "New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents." Biologics 3 (2009): 499-513.  Link to Item
    • Metjian, A, and Lim, W. "ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis?." Hematology Am Soc Hematol Educ Program (2009): 247-249. (Review)  Full Text  Link to Item
    • Metjian, A, and Abrams, CS. "New insights and therapeutics for immune-mediated thrombocytopenia." Expert Rev Cardiovasc Ther 6, no. 1 (January 2008): 71-84. (Review)  Full Text  Link to Item
    • Metjian, A, Roll, RL, Ma, AD, and Abrams, CS. "Agonists cause nuclear translocation of phosphatidylinositol 3-kinase gamma. A Gbetagamma-dependent pathway that requires the p110gamma amino terminus." J Biol Chem 274, no. 39 (September 24, 1999): 27943-27947.  Link to Item
    • Ma, AD, Metjian, A, Bagrodia, S, Taylor, S, and Abrams, CS. "Cytoskeletal reorganization by G protein-coupled receptors is dependent on phosphoinositide 3-kinase gamma, a Rac guanosine exchange factor, and Rac." Mol Cell Biol 18, no. 8 (August 1998): 4744-4751.  Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.